key articles
FGFR3 mutation analysis on voided urine: non-invasive tool to detect BCa recurrence
Tuesday, 29 June 2010- New peptide receptors study findings have been reported by researchers at Erasmus Medical Center, Department of Pathology in Rotterdam, the Netherlands.
"Mutations in the fibroblast growth factor...
Edited by: JV
Clinical outcomes of primary bladder carcinoma in situ after BCG therapy
Tuesday, 22 June 2010- The natural history of primary bladder carcinoma in situ has not been well described. D.C. Chade and colleagues conducted a study to describe patterns of disease recurrence and progression, and identify...
Edited by: JV
Cadherin switching and bladder cancer
Monday, 21 June 2010- Progression to or presentation with muscle invasive disease represents the critical clinical step in bladder cancer, necessitating more aggressive therapy and carrying a significantly worse survival rate....
Edited by: JV
Assessing fluorescence in situ hybridisation (FISH) in bladder cancer surveillance
Wednesday, 26 May 2010- The clinical utility of urine markers in urothelial cancer (UC) surveillance is not established. R. Youssef and colleagues previously evaluated the use of fluorescence in situ hybridisation (FISH) in...
Edited by: JV
Feasibility of lymphadenectomy in laparoscopic radical cystectomy
Tuesday, 18 May 2010- The number of lymph nodes obtained through lymphadenectomy during radical cystectomy has prognostic and therapeutic value.
C. Núñez-Mora and collagues analysed the number of nodes obtained during...
Edited by: JV
Angiogenesis related molecular markers: commonly altered in urothelial bladder carcinoma
Friday, 23 April 2010- A group of researchers in Dallas, Texas (USA) and Quebec (Canada) tested whether the altered immunohistochemical expression of angiogenesis related markers is associated with outcomes of patients with...
Edited by: JV
Patterns of care for early stage bladder cancer
Wednesday, 14 April 2010- Early stage bladder cancer is a heterogeneous disease with a variable risk of progression and mortality. Uncertainty surrounding the optimal care for these patients may result in a mismatch between...
Edited by: JV
Office-based BCa procedures on the rise
Tuesday, 6 April 2010- A new study documents a sharp rise in office-based procedures for bladder cancer after the Centers for Medicare and Medicaid Services (CMS) boosted physician reimbursement for these procedures. The study...
Edited by: ES
Gemcitabine may hold promise for BCG failures
Thursday, 1 April 2010- Gemcitabine might be a second-line treatment option for patients with high-risk non-muscle-invasive bladder cancer, who fail therapy with bacille Calmette-Guérin (BCG), according to Italian...
Edited by: ES
